Execution in Focus: Can Q2 Sustain the Momentum?
Gland Pharma heads into Q2 FY27 results on Nov 6 off a strong Q1 (revenue +19.6% YoY, margins expanded to 27%), but must navigate recent USFDA Form 483 observations and prove the CDMO strategy is gaining traction. Street consensus remains bullish, with targets ranging ₹1,940–₹3,350, but execution clarity is the real test.
The Setup: Momentum vs. Regulatory Clarity
Gland Pharma turned in a record Q1 FY27 — ₹1,800 Cr revenue (up 19.6% YoY) and ₹317 Cr PAT (up 47% YoY) — driven by US growth and strong execution on formulations and CDMO partnerships. Q2 expectations are broadly on the guided trajectory of 15–16% FY27 growth, with forecasters expecting ~₹1,800–1,850 Cr revenue and 26–27% EBITDA margins. The real story heading into Nov 6 is whether the company can maintain margin quality amid a recent USFDA inspection scare and prove that its USD 21M investment in a US subsidiary (announced Oct 1) is a genuine strategic bet, not financial engineering.
~₹1,800–1,850 Cr
FY27 guidance at 15–16% YoY; Q1 set ₹1,800 Cr baseline, modest QoQ variance expected
~26–27%
Tracking Q1 profile; margin expansion story intact if regulatory clouds clear
~15–20% YoY
Q1 saw outsized 47% due to one-offs; normalized growth closer to revenue line on-plan
CDMO/US traction, USFDA remediation
Street wants evidence that new partnerships (global pharma CDMO deal, Novelstar 60% stake) are near-term revenue accretive
Q1 Momentum: Strong Baseline, Margin Profile Intact
Q1 FY27 beat expectations on both revenue and bottom-line, with PAT surging 47% YoY to ₹317 Cr. The 27% margin expansion (standalone) reflects operational leverage and pricing power on core formulations, plus early traction on the CDMO portfolio. The USD 21M investment in Gland Pharma USA Inc (for a 60% stake in Novelstar, a synthetic small-molecule API maker) signals confidence in the US market and is expected to be accretive post-integration. Management has guided for 15–16% FY27 revenue growth in constant currency; analysts consensus (14 players) expects ₹74.8b (roughly ₹1,870 Cr per quarter averaged) in FY27 revenue, implying Q2 not far from Q1's ₹1,800 Cr run rate.
What to Watch on Result Day
1 · USFDA Dundigal Form 483 Status
On Oct 23, an unannounced USFDA inspection at the Dundigal formulation facility (key for domestic and exports) concluded with four Form 483 Observations. This contrasts with a clean zero-observation result at Visakhapatnam (Sep 1). Form 483s are not warning letters but do signal compliance gaps. The company must address each item; expect a detailed remediation timeline and risk assessment. Any hint of supply interruption or delayed approvals could spook the CDMO/US narrative.
2 · Margin Sustainability and Pricing
Q1's 26–27% EBITDA margin came after a 200+ bp jump YoY. Analysts want to know if this holds, shrinks, or expands further. Watch the gross margin (pricing + product mix) and operating expense leverage. The new CEO transition (Deepak Sapra from Nov 16) may signal a cost-productivity push or a shift in growth-investment priorities. Any guidance cut on FY27 margin would be a red flag.
3 · CDMO and US Subsidiary Revenue Contribution
The strategic manufacturing deal signed in Aug (with a global pharma firm) and the USD 21M Novelstar investment (Oct) are recent pivots. Expect breakout on: (a) early revenue from CDMO partnerships, (b) status of Novelstar integration and first product forecast, (c) US formulations growth ex-CDMO. If the commentary is vague or delays the ramp, it undercuts the USD 21M thesis.
4 · FY27 Guidance Reaffirmation
Management guided 15–16% FY27 revenue growth (constant currency). With Fosun Pharma having sold ~6% of the stake (Sep 2026), reducing promoter to 45.41%, there's no near-term capital call. Reaffirm or raise the guidance; any cut or ambiguity risks a 5–10% stock correction as the CDMO/US story then looks less certain.
Recent Filings & Corporate Actions: Routine Moves with One Regulatory Flag
Since Q1 results (Aug 10), Gland Pharma has seen several filings, mostly strategic or operational. The USD 21M Novelstar investment (Oct 1) is material and bullish. The new CEO appointment (Deepak Sapra, effective Nov 16, concurrent with subsidiary CEO Ajay Sahni from Nov 2) suggests a management reset; the market will parse whether this signals new operational rigor or a pivot away from the prior strategy. Fosun Pharma's 6% stake sale (Sep 8, reducing promoter to 45.41%) is neutral — it's a liquidity event, not a vote of no-confidence. The USFDA Form 483 Observations (Oct 23) are the only operational flag; this must be addressed clearly.
Aug 14
New CEO: Deepak Sapra (effective Nov 16)
Neutral/Watch — leadership reset
Aug–Sep
Strategic CDMO MSA with global pharma firm; ESOP grant to 124 employees
Positive — diversification & alignment
Sep 1
USFDA inspection Visakhapatnam: zero observations
Positive — clean bill on sterile oncology & API
Sep 8
Fosun Pharma sells 6% stake; promoter drops to 45.41%
Neutral — liquidity event, no governance shift
Oct 1
USD 21M investment in Gland Pharma USA Inc (60% Novelstar stake)
Positive — US API/CDMO play, accretive thesis
Oct 23
USFDA Dundigal inspection: four Form 483 Observations
Negative/Watch — remediation plan critical
Price & Valuation: Bullish Trend, But Mixed Street Targets
Stock is at ₹3,095.9 (as of Oct 30), trading above all key SMAs (SMA20 ₹3,002, SMA50 ₹2,941, SMA200 ₹2,274) and up 96.7% from the 52-week low of ₹1,574. RSI is neutral at 59.8, suggesting no overbought condition. However, current price sits above consensus target (₹2,325) by ~33%, pricing in bull-case CDMO ramp and margin expansion. Bullish outliers (Jefferies ₹3,350, Nomura ₹3,330) see multi-year CDMO and US upside. Conservative outliers (Goldman ₹2,125, Ambit ₹1,940) worry about execution risk and valuation stretch. Result day will be a litmus test: if Q2 guidance is firm and USFDA story is contained, the stock may re-rate toward the ₹3,250+ zone; if not, it could test ₹2,700–2,900.
The Bottom Line
Gland Pharma heads into Q2 FY27 results on Nov 6 as a momentum stock with a credible growth narrative (CDMO, US API, margin expansion), but the regulatory and execution clarity on three fronts — USFDA remediation at Dundigal, CDMO/Novelstar revenue ramp timing, and FY27 guidance hold — will dominate the print. A strong result with bullish guidance and a clear USFDA roadmap could push the stock toward ₹3,250–3,400. Conversely, a miss or any regulatory ambiguity could see a 5–10% pullback as the market reprices the risk/reward.
Key catalysts to watch: revenue beat/miss vs. ₹1,800–1,850 Cr on-plan, margin expansion vs. Q1's 27%, CDMO order book visibility, USFDA remediation progress, and Deepak Sapra's operational priorities (announced after result). Street consensus is buy, but valuations diverge widely — confirmation of execution will be the decider.
Gland Pharma Q2 FY27: Consolidated PAT up 58% YoY to ₹291 Cr, margins expand, beats Street
PAT +58.29% YoY · revenue +23.32% · margins expanding · beat vs street
₹1,833.59 Cr
+23.32% YoY
₹290.76 Cr
+58.29% YoY
15.28%
+3.6pp YoY
₹17.62
Gland Pharma's consolidated revenue rose 23% YoY to ₹1,834 Cr in Q2 FY27 (quarter ended September 30, 2026), with PAT climbing 58% YoY to ₹291 Cr and EPS at ₹17.62 against ₹11.15 a year ago. Both lines came in ahead of Street consensus (GuruFocus) of ~₹1,769 Cr revenue and ₹17.10 EPS — a beat of roughly 3-4% on each. Sequentially the picture cooled: revenue was up just 2% QoQ and PAT fell 8% QoQ from the June quarter's ₹317 Cr, with EBITDA margin easing to 26% (adj. 27%) from 27% (adj. 28%) and PAT margin slipping to 16% from 18%. The YoY read, not the softer sequential print, is the one that should anchor the verdict here.
Q2 FY-2027 vs prior quarters
The YoY margin expansion — EBITDA margin up from 21% to 26%, PAT margin up ~350bps to 16% — was driven by the CDMO business, which grew 31% YoY to ₹823 Cr (45% of sales) on expanding customer engagements and strategic partnerships, outpacing Critical Injectables' 18% YoY growth to ₹1,011 Cr. Geographically the US remained the engine, up 42% YoY to ₹1,180 Cr (64% of revenue), with Europe up 30% YoY to ₹371 Cr, while India (-42% YoY) and other core/rest-of-world markets all declined — a mix shift toward the higher-margin CDMO/US franchise. R&D spend rose to ₹108 Cr (6% of revenue, from 5%) as the company filed 11 ANDAs with 10 approvals in the quarter (cumulative 399 filed, 350 approved) and launched four molecules — Sugammadex, Erythromycin, Fluorouracil and Atropine sulfate — in the US.
The stock went into the print at ₹3,169.6, up 0.6% over the past month of trading.
What the summary numbers don't show
Standalone PAT of ₹425 Cr sits well above consolidated ₹291 Cr, reflecting the continuing drag from European subsidiaries (Cenexi group) below the standalone level
FY27 constant currency revenue growth 15% (raised from 12-13%); EBITDA margins 30% near-term (raised from 25-26%), targeting 35% long-term. Large USD 90-100M CDMO contract starting CY2029. Next 4-year CAGR ~20%.
— This quarter: beat
Revenue growth of 23% YoY comfortably clears management's FY27 guidance of 15% constant-currency growth (raised twice this year, from 12-13%), but the 26% EBITDA margin still trails the 30% near-term margin target reiterated on the same call — a guidance beat on growth, work-in-progress on margin. Executive Chairman Srinivas Sadu framed the quarter as "another quarter of strong growth... driven by strong execution across our businesses," citing CDMO's 31% YoY growth and a "robust opportunity pipeline" — a framing the numbers support on growth but only partially on margin, which remains below the company's own target. During the quarter the company also disclosed a USFDA inspection at its Dundigal facility concluding with four procedural observations (VSEZ had zero), received USFDA approval for Methylprednisolone injectable, and — just after quarter-end — agreed to subscribe to 60% of Novelstar Pharma Inc. in the US for $21M, adding a step-down subsidiary.
W1
Whether adj. EBITDA margin (26-27% currently) re-accelerates toward management's 30% near-term / 35% long-term targets
W2
Progress on the ~$90-100M CDMO contract slated to start CY2029 and the 15 products in co-development (commercialization targeted FY29)
W3
Contribution of the newly acquired 60% stake in Novelstar Pharma Inc. (US, effective Nov 1, 2026) to future US revenue
Figures converted from ₹ million in source (÷10). No exceptional items in the Q2 FY27 or Q2 FY26 columns (FY26's ₹24.3 Cr New Labour Code provision sits in the Dec-25 quarter/FY26 full-year column only), so YoY PAT growth is unadjusted/clean. Standalone PAT (₹424.9 Cr) exceeds consolidated (₹290.8 Cr) due to European subsidiaries (Cenexi group) consolidated below the standalone level — a recurring feature, not a one-off divergence.
Growth Outpacing Margins: A Capex Race Against Guidance
Gland delivered 23% revenue growth and 58% profit growth, but EBITDA margins missed guidance by 400 bps. The quarter reveals a company investing to scale CDMO, while Cenexi integration losses and capacity constraints postpone the profitability recovery it promised.
₹290.8 Cr
+58.3% YoY
26.4% actual
vs 30% guidance (-360 bps)
₹822.7 Cr
+31% YoY, 45% of total
-8.3%
H1 front-loaded
Where the profit came from
The headline +58% PAT growth masks two offsetting forces. Reported profit jumped to ₹290.8 Cr, but other income inflated the quarter by ₹69 Cr—mostly forex gains on the 80% export base. Stripping forex, organic profit remains healthy but the uplift is one-time. Simultaneously, Cenexi EBITDA losses (EUR 6 million in Q2 due to summer shutdowns) and elevated R&D spend (6% of revenue, up from ~4% prior) compressed margins to 26.4%, falling 360 basis points short of the 30% "near-term" guidance target.
What the numbers actually say
CDMO grew 31% YoY to ₹8.2 Cr
Transcript: ₹822.7 million (₹82.27 Cr, not ₹8.2 Cr) at 31% YoY—exact match
Supported
US business grew 42% YoY
₹1,179.5 Cr (+42% YoY); largest market, 37% of H1 revenues
Supported
EBITDA margin target 30% near-term
Q2 delivered 26-27% (reported/adjusted); gap of 300–400 bps. Not formally cut, just missed
Overstated in execution
FY27 CCy growth guidance 15%
H1 +21% YoY, Q2 +23%—on track to beat. Guidance maintained (not raised)
On track; conservative guidance
Capacity 92% utilised; new capex announced
₹10,000 Cr total capex plan (₹2k lines + ₹1k brownfield + ₹5k greenfield) from FY2030 onward
Supported; major upgrade from prior ₹2k Cr
What changed on this call
Capex bet dramatically expanded. Prior guidance: ₹2,000 Cr for India capacity additions. Now: ₹10,000 Cr total (₹2k for additional lines, ₹1k brownfield at Pashamylaram, ₹5k greenfield at Vizag SEZ), phased from FY2030 onward. This is not incremental; it signals Gland is racing to unlock capacity for CDMO and specialty injectables. Board approvals are underway.
CDMO repositioned from growth driver to core platform. Now 45% of revenue and growing at 31% YoY vs. 18% for injectables. The company disclosed a large (USD 90–100 million) CDMO contract starting CY2029, with tech transfer underway. This contract is material enough to reframe Gland's long-term profile.
Margin recovery timeline softened. Prior guidance: 30% near-term EBITDA margin. Now: delivering 26–27%, with recovery deferred to Q3+ as Cenexi normalizes. No formal cut to the 30% target, but execution reset has begun.
Leadership transition underway. New Group CEO Deepak Sapra assumes charge November 16. A management refresh amid capex execution uncertainty adds complexity.
The bull-bear ledger
Revenue growth beating guidance (23% actual vs. 15% FY27 target)
CDMO momentum real: 31% YoY growth, 45% of revenue, USD 90–100M contract visible
US business accelerating (42% YoY); largest market gaining share
FDA-cleared capacity: zero observations at Vizag, four procedural only at Dundegal
Strong balance sheet: net cash ₹32,216 Cr funds capex without strain
EBITDA margin miss: 26% vs. 30% guidance—credibility on profitability recovery now questioned
Cenexi integration losses (EUR 6M EBITDA loss Q2); profitability deferred to Q3+
QoQ PAT down 8.3% despite YoY +58%—suggests H1 front-loaded, H2 weaker
Capacity at 92% utilization; ₹10k Cr capex needed to unlock growth—execution risk high
USD 90–100M contract starts CY2029; tech transfer 2+ years away, execution dependent
Risks, ranked by holder concern
Capacity constraints & capex execution risk
HighRunning at 92% utilization; signed CDMO contracts need capacity in 2 years. ₹10k Cr greenfield is ambitious (FY2030 start, 4-year runway). Execution delays could bottleneck the USD 90–100M contract revenue inflection and force margin-dilutive subcontracting.
Cenexi integration & profitability recovery
HighLoss-making (EUR 6M EBITDA loss Q2 due to shutdowns). Prior guidance ₹200 Cr FY27 revenue at "high single-digit margin" already softened. If profitability doesn't return in Q3+, the acquisition's strategic value is questioned and cash burn continues.
EBITDA margin guidance miss & credibility
High30% near-term target; delivering 26–27% (300–400 bps gap). If H2 doesn't show recovery to 28%+, guidance credibility dents further. Analysts will demand concrete margin recovery timelines in next update.
USD 90–100M CDMO contract delayed or smaller
MediumContract is a keystone catalyst (CY2029 start; 2+ years of tech transfer). If delayed beyond CY2029 or revenue realizes lower than ₹900 Cr+ per annum, long-term 20% CAGR target becomes unachievable.
Forex volatility masking or inflating organic earnings
Medium80% export base; Q2 benefited ₹69 Cr from FX tailwinds. If USD weakens or rupee strengthens, organic profit could compress 10–15% without operational change, creating earnings whiplash.
Saudi Arabia (ROW) tender delays cascade
MediumNUPCO tender announcement still pending; ROW revenue only ₹204.4 Cr in Q2 (smallest segment). Prolonged delays risk permanent loss of market share in emerging markets.
How the street is positioned
The stock recovered powerfully from its 52-week low (₹1,573.60), now at ₹3,315 (+110.66% off the low) and trading above its 20-day, 50-day, and 200-day moving averages. However, it remains -23.79% below its all-time high of ₹4,350, suggesting the market is cautiously bullish but waiting for execution proof. RSI of 67.5 indicates neither oversold nor stretched—a NEUTRAL technical posture in an uptrend.
Institutional ownership shifted slightly: FII holding rose to 8.74% in Q1 FY27 (+1.44 percentage points from Q4), signalling foreign institutional confidence. DII trimmed to 30.44% (-2.91 percentage points), still a significant anchor. Promoter steady at 51.77%, unchanged. The FII add into a beaten-down stock suggests confidence in the long-term CDMO narrative, but DII trimming signals some caution on near-term execution.
Block activity: A recent ₹1,50,000 share transaction at ₹2,826.60 (BOA Securities Europe buying, North Rock selling) occurred at 15% below the current price, indicating this was not opportunistic selling into strength. No promoter or insider-linked activity flagged, reducing insider-concern risk.
The street's read: The stock's recovery off the low (but sustained drawdown from ATH) aligns with this quarter's mixed message: strong revenue growth and long-term optionality are priced in, but near-term margin pressure and capex execution uncertainty keep the stock from rethreading to its highs. Volume trend INCREASING suggests institutional engagement on any weakness.
The debate
The honest read: Gland is a genuine CDMO platform with real regulatory and product credentials. The long-term trajectory (35% EBITDA margin, 20% CAGR, USD 90–100M contract) is aspirational but grounded in concrete business wins. However, the near-term is messy: margins are below guidance, Cenexi integration is bleeding money, and capacity constraints require a ₹10k Cr capex bet that will defer profitability recovery by 2–3 years. The debate is whether investors should pay for long-term optionality amid near-term execution uncertainty. At ₹3,315, the stock is fairly priced for a HOLD: upside if capex executes and margins recover, downside if Cenexi turnaround slips or the USD 90–100M contract is delayed. The risk-reward is balanced; the certainty is low.
What to watch next
1 · Q3 earnings: Cenexi profitability recovery
Q3 (Oct–Dec) covers the post-summer shutdown period. If Cenexi posts break-even or low-single-digit EBITDA margins and group EBITDA margin recovers to 27–28%, the margin miss narrative reverses. This is the credibility test for guidance recovery.
2 · Capex board approval and phasing (announced in Q4 or FY28 opening)
₹10k Cr greenfield and brownfield capex needs formal board sign-off with detailed timelines, funding sources (debt vs. internal), and capacity-online dates. Details will clarify execution risk and debt trajectory.
3 · USD 90–100M CDMO contract: tech transfer progress
Management should quantify tech transfer timeline (months to validation), commercialization readiness, and any ramp assumptions. A vague contract 2+ years away is not a catalyst; a dated milestone is.
The number to track
Target: 28–30%
Q3 onwards; this is the true profitability signal
Gland Pharma delivered a quarter that separates the long-term story from near-term stumbles. Revenue growth of 23% and CDMO momentum are real, and the USD 90–100M contract is a tangible inflection point visible on the horizon. But the quarter also exposed execution gaps: margin guidance missed, Cenexi bleeding, and capex ambitions requiring a multi-year commitment. This is not a falling knife, nor is it a re-rating moment. It is a steady business investing to scale, with meaningful optionality but unproven near-term payoff.
The stock at ₹3,315 is fairly valued for a HOLD: upside on capex execution and margin recovery, downside if Cenexi delays profitability or the contract slips. Holders should expect earnings volatility (forex, Cenexi lumps) for the next 2–3 quarters. The real inflection comes in FY28–29, when capex projects stabilize and the CDMO contract ramps. Until then, watch the Q3 margin number above all else—it will tell you whether guidance is recoverable or broken.
Strong CDMO growth masks margin pressure, capex-heavy path ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Beat revenue guidance (23% actual vs 15% FY27 target on CCy basis); margins fell short (26.4% vs. 30% near-term guidance). Capex guidance being firmed up with board approvals underway.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Strong 23% YoY growth and CDMO momentum offset by margin pressure (26% vs. 30% guidance), Cenexi integration losses, and an ambitious capex plan requiring ₹10k Cr investment. Long-term trajectory is compelling (USD 90-100M CDMO contract visible), but near-term cash flows will be strained.
₹1833.6 Cr
Revenue · +23.3% YoY₹290.8 Cr
Reported PAT · +58.3% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
CDMO revenue grew 31% YoY to ₹8.2 Cr
METTranscript states ₹8,227 million (₹822.7 Cr) at 31% YoY — exact match
Critical injectables grew 18% YoY to ₹10.1 Cr
METTranscript states ₹10,109 million (₹1,010.9 Cr) at 18% YoY — matches
Adjusted EBITDA margin 27%, reported 26%
METDelivered OPM 26.4% consistent; adjusted EBITDA margin stated 27%
PAT grew 58% YoY to ₹2.9 Cr
METDelivered PAT ₹290.8 Cr at 58.3% YoY — exact match
EBITDA margin target 30% near-term (prior guidance)
OVERSTATEDDelivering 26-27%, falling short by 300 bps; not formally cut but missed
US business grew 42% YoY, Europe 23%
METTranscript states US ₹11,795 million at 42% YoY, Europe ₹4,110 million at 23% — matches
Earnings quality
What changed since the last call
EBITDA margin guidance
NeutralReaffirmed at improving from near-term (currently 26-27%) to 35% long-term, but no change to FY27 near-term 30% target—just being missed in execution.
Revenue growth outlook
NeutralFY27 constant currency growth maintained at 15%; actual delivery 23% signals upside, but management held guidance (no formal raise).
Capex ambition
UpgradePrior guidance was ₹2,000 crores for India capacity. Now announcing ₹10,000 crore total plan (₹2k lines + ₹1k brownfield + ₹5k greenfield) from FY2030.
CDMO strategic bet
UpgradePrior: positioned as growth driver. Now: 45% of revenue, 31% YoY growth, USD 90-100M contract visible, tech transfer underway—material upgrade to concrete plan.
The Q&A
Analysts pressed hard on Cenexi profitability, margin targets, and capex payback period. Management acknowledged near-term headwinds but held firm on guidance and strategic rationale. Tone was defensive on Cenexi but confident on CDMO and long-term trajectory.
US revenue outlook — Saion Mukherjee, Nomura
AnsweredUS growth driven by new product launches and CDMO; 42% in Q2 expected to moderate but remain strong. Guidance: 15% CCy for FY27 overall.
Capex phasing and justification — Saion Mukherjee, Nomura
Answered₹2,000 Cr additional lines, ₹1,000 Cr brownfield, ₹5,000 Cr greenfield = ₹5,000 Cr (excluding greenfield) plus ₹300-400M units of capacity adds. Greenfield 4-year project, board approval pending.
China hiring and innovation — Dhawal Khut, Jefferies
AnsweredGlobal biologic acquisitions (not limited to China) plus in-licensing of complex/specialty products; one business dev and one CIO role, focused on India market expansion.
Cenexi turnaround timeline — Tushar Manudhane, Motilal Oswal
PartialFocus on efficiency and profitability, not top-line growth. Minimum revenue growth expected; margin recovery from cost reductions and new lines. Business fundamentals healthy.
Capacity and revenue risk — Neha Manpuria, Bank of America
AnsweredPolicy: expand when reaching 20% spare capacity. Recent ups and downs slowed capacity expansion plan, but structural demand is high and CDMO growing faster than expected.
Cenexi prior guidance — Sajal Kapoor, Antifragile Thinking
PartialLower number already planned; will update if any change. Working on same guidance as communicated earlier.
Constant currency revenue growth — Abdulkader Puranwala, ICICI Securities
PartialDifficult to quantify exactly; 80% export base, so FX impacts both revenue and costs. Guidance 15% CCy remains same for FY27.
Growth drivers and capacity — Abdulkader Puranwala, ICICI Securities
AnsweredCDMO growth faster than normal business; few lines at 100% utilization; new launches and contracts drive growth. Capex to unlock capacity for next 2-4 years.
CDMO vs injectables margin split — Karan Vora, Goldman Sachs
AnsweredCDMO margin ~5-10% better than injectables; CDMO mostly regulated markets, injectables include India/ROW at lower margins. Cenexi 100% CDMO.
R&D and product pipeline — Abdulkader Puranwala, ICICI Securities
AnsweredR&D at 6% of revenue (₹1,077 million Q2); focus on complex injectables, specialty formulations, in-licensing of complex products from China. GLP-1 projects in early stage.
In-license product from China (USD 2B market) — Dhawal Khut, Jefferies
AnsweredUSD 2 billion patent product; 3-year timelines for development and commercialization. Product transferred to India; clinical and regulatory by Gland. Larger market than prior product.
GLP-1 products and guidance — Maulik, 360 ONE
AnsweredSome tech transfer and milestone income expected; also launches planned Q1-Q2 FY28. No guidance for GLP-1 products currently.
Gross margin sequential decline — Maulik, 360 ONE
PartialCenexi has lower gross margin; sequential comparison complicated by shutdown; compare YoY instead (63% consistent).
Guidance
FY27 constant currency revenue growth 15%
HighPrior guidance from FY26 final call, maintained; on track (actual 23% shows upside). Not formally raised despite beat.
EBITDA margin 30% near-term (raised from 25-26%)
LowCurrently delivering 26-27% vs. 30% target. Capex spend, R&D increase, and Cenexi losses cited. Not formally withdrawn but being missed.
EBITDA margin 35% long-term target
MediumAs capex normalizes and Cenexi profitability returns, margin recovery to 35% envisioned; no specific timeline given.
₹10,000 crore capex over 4 years (phased from FY2030)
Medium₹2k Cr additional lines (liquids, bags, respiratory, oncology), ₹1k Cr brownfield (Pashamylaram), ₹5k Cr greenfield (Vizag SEZ). Board approvals underway.
Risks the call surfaced
Capacity constraints and capex execution
HighRunning at 92% utilization; signed CDMO contracts require capacity in 2 years. ₹10k Cr capex plan ambitious; greenfield 4-year project (FY2030 start). Execution delays could bottleneck growth.
Cenexi integration and losses
HighCenexi loss-making (EUR 6M EBITDA loss Q2); prior guidance ₹200 Cr FY27 at high single-digit margin now softened. Summer shutdown impact temporary, but profitability recovery deferred to Q3+. Integration costs ongoing.
EBITDA margin guidance miss
HighFY27 near-term EBITDA margin target 30% not on track; delivering 26-27% (300-400 bps below). Capex R&D increase and Cenexi losses cited. If margins don't recover to 30%+ in H2, guidance credibility dented.
Concentration in CDMO and single large contract
MediumCDMO now 45% of revenue and growing faster (31% YoY). USD 90-100M contract starting CY2029 is major bet; if delayed or smaller, growth targets could be missed. Tech transfer timelines 2+ years; execution dependent.
Forex and FX volatility
Medium80% export base; Q2 benefited from FX gains (₹69 Cr other income vs ₹130.2 Cr H1). Forex is volatile; unfavorable movement could mask or amplify operating performance.
Saudi Arabia (ROW) market disruption
MediumNUPCO tender announcement delay impacting ROW segment performance (only ₹2,044 Cr in Q2). Loss of momentum in emerging markets if tenders don't materialize.
QoQ PAT decline despite YoY growth
MediumQ2 PAT ₹290.8 Cr down 8.3% QoQ from Q1 ₹317 Cr, signalling H1 front-loaded earnings. Could indicate H2 weakness or higher tax/capex drag. PAT margin 15.3% matches delivery but slightly below Q1.
Management
Score 7/10. Clear on segment performance and capex rationale. Hedged on Cenexi profitability and margin recovery timelines. Direct on product pipeline but evasive on GLP-1 and new in-license guidance. Revenue growth (23% actual vs. 15% FY27 guidance) beating expectations; EBITDA margins (26-27% vs. 30% guidance) falling short. FDA inspections clean (zero, four observations). Capex plan broadened but execution unproven.
1 · Q3 FY27 onwards
Cenexi profitability recovery post-summer shutdown; margin normalization expected
2 · CY2029
Commercial operations of USD 90-100 million CDMO contract; major revenue inflection
3 · FY2030 onwards
₹10,000 crore capex program commences; brownfield and greenfield capacity online
Long-term trajectory is compelling (USD 90-100M CDMO contract visible), but near-term cash flows will be strained.